Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.
作者信息
Greiner Jochen, Hofmann Susanne, Schmitt Michael, Götz Marlies, Wiesneth Markus, Schrezenmeier Hubert, Bunjes Donald, Döhner Hartmut, Bullinger Lars
机构信息
Department of Internal Medicine III, University of Ulm, Ulm, Germany
Department of Internal Medicine, Diakonie Hospital Stuttgart, Ulm, Germany.
出版信息
Haematologica. 2017 Dec;102(12):e499-e501. doi: 10.3324/haematol.2017.176461. Epub 2017 Sep 21.
Abstract
摘要
相似文献
1
Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.伴有核磷蛋白1突变的急性髓系白血病：一种具有免疫原性的急性髓系白血病亚型及免疫检查点抑制的潜在候选对象。
Haematologica. 2017 Dec;102(12):e499-e501. doi: 10.3324/haematol.2017.176461. Epub 2017 Sep 21.
2
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).一个单突变数学模型可以解释伴有核磷蛋白（NPM1）突变的急性髓系白血病的年龄发病率。
Haematologica. 2008 Aug;93(8):1219-26. doi: 10.3324/haematol.13209. Epub 2008 Jul 4.
3
Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.细胞质突变型核仁磷酸蛋白在原发性白血病细胞以及重症联合免疫缺陷（SCID）小鼠的NPMc+急性髓系白血病异种移植模型中是稳定的。
Haematologica. 2008 May;93(5):775-9. doi: 10.3324/haematol.12225. Epub 2008 Mar 26.
4
Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family.同一家族中同时发生伴有核仁磷酸蛋白（NPM1）突变的急性髓系白血病。
Leukemia. 2009 Jan;23(1):199-203. doi: 10.1038/leu.2008.170. Epub 2008 Jul 3.
5
Nucleophosmin gene mutation in acute myeloid leukemia patients.急性髓系白血病患者的核磷蛋白基因突变
Saudi Med J. 2010 May;31(5):582-4.
6
Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.一种用于检测急性髓系白血病中突变型核磷蛋白1存在的流式细胞术方法的开发。
Hematol Oncol Stem Cell Ther. 2015 Sep;8(3):106-14. doi: 10.1016/j.hemonc.2015.06.009. Epub 2015 Jul 9.
7
A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis.单个中心分析核仁磷酸蛋白在急性髓细胞白血病中的作用：联合免疫组织化学与分子突变分析的价值。
Haematologica. 2013 Oct;98(10):1532-8. doi: 10.3324/haematol.2012.079806. Epub 2013 May 28.
8
Quantitative detection of circulating nucleophosmin mutations DNA in the plasma of patients with acute myeloid leukemia.急性髓系白血病患者血浆中循环核仁磷酸蛋白突变DNA的定量检测
Int J Med Sci. 2015 Jan 1;12(1):17-22. doi: 10.7150/ijms.10144. eCollection 2015.
9
The human nucleophosmin 1 mutation A inhibits myeloid differentiation of leukemia cells by modulating miR-10b.人类核仁磷酸蛋白1突变A通过调节miR-10b抑制白血病细胞的髓系分化。
Oncotarget. 2016 Nov 1;7(44):71477-71490. doi: 10.18632/oncotarget.12216.
10
NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes.伴 NPM1 突变的单核或髓系来源的急性髓系白血病具有独特的免疫表型。
Leuk Res. 2013 Jul;37(7):737-41. doi: 10.1016/j.leukres.2013.03.009. Epub 2013 Apr 16.
引用本文的文献
1
Immune checkpoints regulate acute myeloid leukemia stem cells.免疫检查点调节急性髓系白血病干细胞。
Leukemia. 2025 Apr 2. doi: 10.1038/s41375-025-02566-x.
2
Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia.突变型核仁磷酸蛋白1在急性髓系白血病治疗中的免疫治疗潜力
Cancers (Basel). 2024 Oct 10;16(20):3443. doi: 10.3390/cancers16203443.
3
NPM 1 Mutations in AML-The Landscape in 2023.急性髓系白血病中的NPM 1突变——2023年的概况
Cancers (Basel). 2023 Feb 12;15(4):1177. doi: 10.3390/cancers15041177.
4
Targeted therapy in NPM1-mutated AML: Knowns and unknowns.NPM1 突变型急性髓系白血病的靶向治疗：已知与未知
Front Oncol. 2022 Sep 27;12:972606. doi: 10.3389/fonc.2022.972606. eCollection 2022.
5
Current status and future perspectives in targeted therapy of NPM1-mutated AML.NPM1 突变型 AML 的靶向治疗的现状与展望。
Leukemia. 2022 Oct;36(10):2351-2367. doi: 10.1038/s41375-022-01666-2. Epub 2022 Aug 25.
6
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.全基因组关联研究鉴定出急性髓细胞白血病的易感性位点。
Nat Commun. 2021 Oct 29;12(1):6233. doi: 10.1038/s41467-021-26551-x.
7
Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.新抗原特异性 T 细胞免疫反应：NPM1 突变型急性髓系白血病的范例。
Int J Mol Sci. 2021 Aug 25;22(17):9159. doi: 10.3390/ijms22179159.
8
T cell optimization for graft-versus-leukemia responses.T 细胞优化移植物抗白血病反应。
JCI Insight. 2020 May 7;5(9):134939. doi: 10.1172/jci.insight.134939.
9
B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles.B7阳性和B7阴性急性髓系白血病表现出不同的T细胞成熟谱、免疫检查点受体表达及欧洲白血病网风险谱。
Front Oncol. 2020 Mar 13;10:264. doi: 10.3389/fonc.2020.00264. eCollection 2020.
10
Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.免疫检查点抑制可增强 AML 患者针对包括白血病祖细胞在内的集落形成细胞的特异性 T 细胞免疫反应。
Cancer Immunol Immunother. 2020 Apr;69(4):629-640. doi: 10.1007/s00262-020-02490-2. Epub 2020 Feb 4.
本文引用的文献
1
Combination immunotherapy: a road map.联合免疫疗法：路线图。
J Immunother Cancer. 2017 Feb 21;5:16. doi: 10.1186/s40425-017-0218-5. eCollection 2017.
2
The expanding role of immunotherapy.免疫疗法的作用不断扩大。
Cancer Treat Rev. 2017 Mar;54:74-86. doi: 10.1016/j.ctrv.2017.01.008. Epub 2017 Feb 11.
3
PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.异基因造血干细胞移植后复发的急性髓系白血病患者的程序性死亡受体 1 检查点阻断治疗。
Bone Marrow Transplant. 2017 Feb;52(2):317-320. doi: 10.1038/bmt.2016.274. Epub 2016 Nov 28.
4
The emerging role of immune checkpoint inhibition in malignant lymphoma.免疫检查点抑制在恶性淋巴瘤中的新兴作用。
Haematologica. 2017 Jan;102(1):30-42. doi: 10.3324/haematol.2016.150656. Epub 2016 Nov 24.
5
Engineered T cells: the promise and challenges of cancer immunotherapy.工程化T细胞：癌症免疫疗法的前景与挑战
Nat Rev Cancer. 2016 Aug 23;16(9):566-81. doi: 10.1038/nrc.2016.97.
6
Biomarkers for Immunotherapy: Current Developments and Challenges.免疫疗法的生物标志物：当前进展与挑战
Am Soc Clin Oncol Educ Book. 2016;35:e493-503. doi: 10.1200/EDBK_160766.
7
Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia.与 A/D 型核磷蛋白突变相关的 HLA I 类分子谱改变提示急性髓系白血病中可能存在抗核磷蛋白免疫反应。
PLoS One. 2015 May 20;10(5):e0127637. doi: 10.1371/journal.pone.0127637. eCollection 2015.
8
Immune checkpoint blockade: a common denominator approach to cancer therapy.免疫检查点阻断：癌症治疗的一种通用方法。
Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6.
9
Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.NPM1 突变型急性髓系白血病患者的异基因造血干细胞移植：来自 SAL-AML 2003 试验中前瞻性 HLA 配型后供者与无供者分析的结果。
J Clin Oncol. 2015 Feb 10;33(5):403-10. doi: 10.1200/JCO.2013.54.4973. Epub 2014 Dec 29.
10
Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy.携带NPM1突变的急性髓系白血病患者的白血病干细胞是靶向免疫治疗的候选对象。
Leukemia. 2014 Aug;28(8):1759-62. doi: 10.1038/leu.2014.116. Epub 2014 Mar 28.
Zotero 插件